Genetic medicine has fast become one of biotech’s biggest growth stories — treatments that were unimaginable a decade ago are now making a profound difference to people’s health and generating real revenue. The companies behind them are reshaping how rare and previously untreatable diseases are managed, creating a new market for investors.
The science is maturing fast, and capital is following it. This watchlist spans the spectrum. What underpins these companies is an impressive and diverse development pipeline that connects state-of-the-art science to communities with chronic illnesses that go underrecognized by much of the market.
BridgeBio Pharma (BBIO) Attruby ATTR-CM Treatment
The real story behind BridgeBio’s recent success is Attruby (acoramidis), its ATTR-CM therapy. Q1 2026 U.S. Attruby revenue hit $180.6 million. This success is a result of patient and practitioner confidence brought on by the treatment’s 49.3% reduction in cardiovascular mortality through Month 54, representing the earliest timepoint with this magnitude of benefit in an open-label extension study.
The drug’s success has also benefited from redoubled confidence in stabilizer drugs over silencers after the unsuccessful test of AstraZeneca’s ATTR-CM silencing drug, Wainua. This, combined with Attruby’s status as a “near complete” stabilizer of TTR, the protein which causes the ATTR-CM heart disease when destabilized, has underpinned the drug’s growing commercial success. This explains why the 2026 worldwide sales forecast for Attruby went from $828 million to $1.02 billion, with peak sales estimates now at $3.5 billion.
Given Attruby’s ongoing success, it is unsurprising that 22 analysts have given the BBIO stock a ‘Strong Buy’ rating, after the stock price target increased by 29.68% to $105.26. That’s on top of the $1 billion in preferred equity the company has raised from HealthCare Royalty, a business of KKR, strengthening the company’s balance sheet.
Vertex Pharmaceuticals (VRTX) Medical Mergers
Vertex has had an unusually strong run starting on July 1, when the FDA expanded the CASGEVY label to patients as young as 2 with sickle cell disease or transfusion-dependent beta thalassemia. CASGEVY’s label expansion has broadened the drug’s eligible market beyond Vertex’s core cystic fibrosis franchise.
In early July, Vertex announced it would acquire Crinetics Pharmaceuticals for roughly $10 billion at $85 per share. This acquisition will add the approved drug PALSONIFY and pipeline candidate atumelant to Vertex’s business and mark an expansion into endocrinology. And the momentum has not stopped there: JOURNAVX, an oral pain signal inhibitor developed by Vertex that launched in January 2025, saw an 8% increase in total revenue in Q1 of 2026 alone.
This diverse and growing portfolio has won investor confidence, with many of them assessing Vertex’s stock as a ‘buy’ after it gained about 5% this year. Analyst sentiment has followed — UBS raised its price target to $583 from $545. Between the CASGEVY label expansion, the Crinetics deal, and JOURNAVX’s commercial ramp, VRTX has had one of the more catalyst-dense, fundamentals-backed stretches in the group.
Intellia Therapeutics (NTLA) Intellia Gene-Editing
Intellia is a CRISPR gene-editing company working on curative therapeutics using gene editing technology to target hereditary angioedema disease. In April 2026, its global Phase 3 HAELO trial became the first positive Phase 3 readout for an in vivo CRISPR therapy, freeing most patients from primary and ongoing therapy for the entirety of the six-month evaluation period. Intellia has since initiated a rolling biologics license application submission with the FDA, expecting to complete it in the second half of 2026, with a potential U.S. launch in the first half of 2027 if approved.
Analysts are treating the NTLA stock as a ‘buy’, citing its 143.9% increase in stock price to $26.17. The clinical story is genuinely exciting (a first-of-its-kind CRISPR win), but the young pipeline means more disagreement among analysts here than with BridgeBio’s more incremental, already-de-risked pipeline.
The Investor’s Verdict: BridgeBio, Attruby, and the Road Ahead
What unites BridgeBio, Vertex, and Intellia is a shared bet that precision science can finally reach patients underserved by medicine through scale, commercial focus, or technological leap.
Each of these stories carries its own dynamics worth tracking — Intellia’s still hinges on a single upcoming regulatory decision, and the wider ATTR-CM field will keep evolving as more therapies advance. But taken together, these three companies offer a compelling cross-section of genetic medicine’s growth curve, from early-stage science to established commercial scale, with real momentum building across the board heading into the second half of 2026.